Chemi-Verse™ CDK1/CyclinA2 Kinase Assay Kit
The Chemi-Verse™ CDK1/CyclinA2 Kinase Assay Kit is designed to measure CDK1 (cyclin dependent kinase 1)/CyclinA2 kinase activity for screening and profiling applications using ADP-Glo™ as a detection reagent. The assay kit comes in a convenient 96-well format, with enough purified recombinant CDK1/CyclinA2 complex, kinase substrate, ATP, and kinase assay buffer for 100 enzyme reactions.
- ADP-Glo™ Kinase Assay (Promega #V6930)
- DTT (Dithiothreitol), 1M, optional
- Microplate reader capable of reading luminescence
- Adjustable micropipettor and sterile tips
- 30°C incubator
| Catalog # | Name | Amount | Storage |
| 40100 | CDK1/CyclinA2, GST-Tag* | 2 µg | -80°C |
| 79334 | 5x Kinase Buffer 1 | 1.5 ml | -20°C |
| 79686 | 500 µM ATP | 50 µl | -20°C |
| 10x CDK Substrate Peptide 1 | 50 µl | -20°C | |
| 79696 | White 96-well plate | 1 | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
CDK1 (cyclin-dependent kinase 1), also known as cell division cycle protein 2 homolog, belongs to the serine/threonine protein kinase family and is involved in cell cycle regulation. CDK1 is regulated by multiple partners, being activated by other CDK family members like CDK7 and CDK2, but also by CDC25C, DNMT3A (DNA (cytosine-5)-methyltransferase 3A, HDAC3 (histone deacetylase 3), myc and others. Proteins like p21, HDAC4 and SUMO1 (small ubiquitin-related modifier 1) are involved in its inactivation. CDK1 complexed with cyclins in turn regulates multiple targets, both tumor suppressors and promoters, via phosphorylation. These include HIF1α (hypoxia-inducible factor 1-alpha), BCL2 (B-cell lymphoma 2) and EZH2 (enhancer of zeste homolog 2). CDK1 is linked to several cancer types, including colon carcinoma, hepatocellular carcinoma, lung and prostate cancer. The use of inhibitors targeting CDK1 can effectively stop cancer cell proliferation and has shown great promise in preclinical studies. One example is Dinaciclib, a high affinity inhibitor of CDK1, 2, 5 and 9, for the treatment of refractory chronic lymphocytic leukemia (CLL). The use of CDK inhibitors carries side effects due to role of CDK proteins in cell biology, so the development of CDK1 specific inhibitors and a better understanding of the impact of such therapies will benefit oncology patients.
Wang Q., et al., 2023 npj Precision Oncology 7:58
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.